Gen9, Inc., a pioneer in DNA synthesis and assembly technology, has received two new US patents that further expand its industry-leading portfolio of intellectual property.

The patents, US Patent Nos. 9,023,601 and 9,051,666, provide broad protection for features that are at the heart of Gen9’s proprietary DNA synthesis and assembly technology. Among other aspects, the patents cover novel processes, compositions and devices directed to DNA fragments designed for use in DNA assembly, as well as amplification of engineered fragments of longer-length DNA sequences. They represent the newest additions to Gen9’s robust patent estate uniquely geared toward making high-fidelity synthetic genes accessible to the greater synthetic biology community.

“As the first and only company to develop and operate an industrialized, massively-parallel manufacturing platform for DNA synthesis and assembly, Gen9 has driven innovation across a number of critical areas, enabling us to produce high quality DNA at a scale, construct length and value never before possible,” said Devin Leake, Gen9 vice president of research and development and operations. “These new patents represent some of the unique technologies that power our BioFab platform, allowing us to meet the soaring demand in synthetic biology.”

“We believe synthetic biology will fuel the future of advancements in everything from therapeutics to clean technology to agriculture,” said Kevin Munnelly, president and chief executive officer of Gen9. “We are dedicated to the further development of transformative DNA production technologies and we’re excited to continue working with our customers as they put the power of synthetic biology to work.”